Drug quality cases

In recent years, domestic drug quality and safety cases: In May 2006, when the "Armillarisin A Injection" produced by Qiqihar No.2 Pharmaceutical Co., Ltd. was initially identified as a counterfeit drug, in order to ensure the safety of public medication, the State Food and Drug Administration of the United States resolutely decided to stop selling and using all drugs produced by Qiqihar No.2 Pharmaceutical Co., Ltd. nationwide, and at the same time required local drug supervision departments to seal up and detain them on the spot within their jurisdiction. In August 2006, Anhui Huayuan Bio-pharmaceutical Co., Ltd. illegally produced drugs, which led to an adverse drug event of clindamycin phosphate glucose injection. After investigation, the clindamycin phosphate glucose injection produced by the company in June-July 2006 was not sterilized according to the approved process parameters, which reduced the sterilization temperature, shortened the sterilization time, increased the loading capacity of the sterilization cabinet, and affected the sterilization effect. At present, there are 1 1 person who died after injecting clindamycin phosphate glucose injection: 2 in Heilongjiang, Shaanxi and Hunan, and 2 in Inner Mongolia, Liaoning, Hebei, Hubei and Sichuan. On June 5438+1October 2 1 day, 2007, the Ministry of Health and the State Food and Drug Administration of the United States announced that the intravenous immunoglobulin products produced by Guangdong Baiyi Pharmaceutical Co., Ltd. had serious violations and decided to temporarily stop selling and using intravenous immunoglobulin products produced by Guangdong Baiyi Pharmaceutical Co., Ltd. In May, 2007, the public security and health departments of Hebei Province carried out a special inspection activity of "Rabies Vaccine for Human Use" and seized "Rabies Vaccine for Human Use" 18 batches, more than 44,000 semi-finished products and 2 fake dens from four units including Henan Puxin Bioengineering Co., Ltd., Foer Biopharmaceutical Co., Ltd., Changchun Institute of Biological Products and Dalian Jingang Andy Biological Products Co., Ltd.. In September, 2007, the US Food and Drug Administration in Shanxi issued a drug quality announcement, saying that 88 batches of drugs, including Shuanghuanglian Oral Liquid produced by Qiqihar No.2 Pharmaceutical Factory and Bupleurum Injection produced by Shuanghe Pharmaceutical Company in Jin Xin, Shanxi, were unqualified, accounting for 16.5% of the total. In March 2008, Jiangxi Drug Administration reported a case of "non-drugs passing off as drugs" jointly investigated by government departments, and seized more than 3800 bottles of counterfeit drugs and health food/KLOC-0, involving more than 60 kinds of drugs and health food, and more than 70,000 boxes, with a case value of more than 2 million yuan.